Novartis Consumer Health Inc. voluntarily recalled several products, including Excedrin Migraine, on January 8, saying that the recall was “precautionary following consumer complaints of chipped and broken pills and inconsistent bottle packaging line clearance practices possibly resulting in mixed tablets.”
Since then, some of the people who depended on Excedrin Migraine have resorted to desperate measures, including paying outrageous prices for it online.
Wednesday, an update was posted on the Excedrin Facebook page:
“We’re excited to announce to our loyal Excedrin fans that we have resumed production of Excedrin, and that Excedrin Migraine will be our first product to return to the market. We expect the product to begin appearing on store shelves in October. And we are working diligently to get Excedrin Extra Strength back to store shelves as soon as possible. Thanks for your patience and for your loyal support of Excedrin.”